Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K/A Current report
- 23.1 Consent of Ernst & Young LLP, Independent Auditors of the Abbreviated Financial Statements of the Pediatrics Product Portfolio of Cerecor, Inc.
- 99.1 Audited Historical Abbreviated Financial Statements for the Pediatrics Product Portfolio of Cerecor, Inc. As of September 30, 2019, and December 31, 2018 and for the Nine Months Ended September 30, 2019 and the Year Ended December 31, 2018
- 99.2 Unaudited Historical Abbreviated Financial Statements for the Pediatrics Product Portfolio of Cerecor, Inc. As of September 30, 2018 and for the Nine Months Ended September 30, 2018
- 99.3 Unaudited Pro Forma Condensed Combined Balance Sheet As of June 30, 2019 and Statement of Operations for the Year Ended June 30, 2019 and Three Months Ended September 30, 2019
AYTU similar filings
- 13 Feb 20 Aytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% Sequentially
- 24 Jan 20 Submission of Matters to a Vote of Security Holders
- 15 Jan 20 Entry into a Material Definitive Agreement
- 10 Jan 20 Index to Abbreviated Financial Statements
- 26 Dec 19 Regulation FD Disclosure
- 11 Dec 19 Other Events
- 2 Dec 19 Aytu BioScience Announces Launch of Natesto® U.S. Co-Promotion with Acerus Pharmaceuticals
Filing view
External links